Benefits of Retained Insulin for Good Health (BRIGHT)
Understanding the Impact of Endogenous Insulin Secretion on Clinical Outcomes in Type 1 Diabetes and the Optimal Approach to C-peptide Measurement for Outcome Prediction
The purpose of this research is to understand the impact of retained endogenous insulin (as measured by C-peptide) on quality of life and related outcomes in people living with insulin treated diabetes, and, in those living with type 1 diabetes, to determine the pragmatic and non-pragmatic C-peptide measures which have the strongest association with clinical benefit (including repeated home samples and derived measures of beta cell function). The investigators will do this in two ways:
Firstly, the investigators will extend a large existing prospective study of new adult onset diabetes (Getting the Right Classification and Treatment From Diagnosis in Adults With Diabetes (StartRight)) https://clinicaltrials.gov/ct2/show/NCT03737799) which has followed 1800 participants for median 4 years from diabetes diagnosis. Participants with insulin treated diabetes will be invited to take part in a further research visit remotely or face to face. The investigators will assess the longitudinal relationship between C-peptide and the available quality of life, mental health status and healthcare utilisation measures over up to 9 years from diabetes diagnosis and assess additional measures in cross sectional analysis.
In the second part of this research, the investigators will utilise cohorts of over 2500 participants with type 1 diabetes, measured C-peptide and consent to recontact to recruit 200 participants with a range of C-peptide. Eligible participants with C-peptide measured in clinical care may also be invited to take part. The investigators will undertake detailed assessment of complex and pragmatic measures of C-peptide and beta cell function and compare performance in predicting glycaemic outcomes (using data from continuous glucose monitors) and (where relevant) patient reported outcomes.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
The purpose of this study is to understand the possible benefits of restoring insulin secretion in people living with diabetes, and to understand how insulin secretion can be best measured in people living with diabetes.
Most people living with type 1 diabetes stop making their own insulin, this means that insulin injections are needed to survive. It also means their blood glucose is variable, meaning it is very difficult to control blood glucose levels. This is in contrast to type 2 diabetes, where most people keep making their own insulin, and loss of insulin production is uncommon.
Previous research has shown that some people with type 1 diabetes keep making some of their own insulin, and this can be very helpful for their blood glucose control. However, there is limited information on long term benefits of making insulin, and other possible benefits, such as on wellbeing, have not been studied. It is important that the full benefits of making insulin are known as new treatments have been developed to preserve insulin secretion in type 1 diabetes, and/or to restore insulin secretion. These treatments are expensive and can have side effects, and have been studied only in small studies for a short amount of time. It is important to fully understand the likely long-term benefits of preserving or restoring insulin secretion to know whether healthcare providers like the NHS should fund these treatments.
At present research studies that are testing new treatments to preserve or restore a person's insulin production need to frequently test insulin secretion, using a test called a mixed meal tolerance test that needs to be undertaken in a hospital setting and takes at least 2.5 hours. This makes these studies difficult to take part in, and expensive to run. Insulin production can now be measured at home, on a finger-prick test, but more information is needed on the best way to do the home test for these kinds of studies.
This research has two parts. In the first part of this research the investigators will measure insulin secretion (using a test called C-peptide) in 500 people with insulin treated diabetes who have already taken part in a large recent study that measured their insulin secretion, and other important measures such as their quality of life and use of healthcare services, every year for up to 4 years after diabetes diagnosis. There will be assessment of participants' quality of life and other measures related to diabetes. The investigators will use this information, and the information already collected in the study, to understand the effects of retaining or loosing insulin production over up to 9 years from diabetes diagnosis, and compare whether this differs in type 1 and 2 diabetes.
In the second part of this research the investigators will recruit 200 participants with type 1 diabetes who have had their insulin secretion measured in part one of this research, in other research or in clinical care. Information from this previous testing will be used to ensure participants are recruited with a range of insulin production. Participants will attend a research facility for assessment of their insulin production over 2 hours after a liquid meal similar to a milkshake. Participants will then undertake this test at home, using finger-prick samples after the same liquid meal, and after 3 of their own normal meals. Participants will also monitor their glucose over 2 weeks using a device called a continuous glucose monitor. This information will be used to understand if home measures are as accurate as the test in the research facility, and work as well in predicting a person's risk of low glucose (hypoglycaemia) and how variable their glucose is.
The end result of this research will be important information to inform the design of studies of new treatments to preserve or restore insulin secretion for people living with diabetes and understand the likely long-term benefits of these treatments.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: BRIGHT Study Research Team
- Номер телефона: +44 1392408181
- Электронная почта: rduh.brightstudy@nhs.net
Места учебы
-
-
-
Bath, Соединенное Королевство, BA1 3NG
- Рекрутинг
- D1 Wolfson Centre Research and Development
-
Контакт:
- Diabetes and Lipids Research Team (Bath)
- Номер телефона: +44 1225821304
- Электронная почта: ruh-tr.DiabetesAndLipidsResearch@nhs.net
-
Главный следователь:
- Rachel Mathias
-
Bristol, Соединенное Королевство, BS10 5NB
- Рекрутинг
- Clinical Research Centre
-
Главный следователь:
- Georgina Russell
-
Контакт:
- Diabetes Research Team (Bristol)
- Номер телефона: +44 1174148125
- Электронная почта: nbn-tr.nbtdiabetesresearch@nhs.net
-
-
Cornwall
-
Truro, Cornwall, Соединенное Королевство, TR1 3LJ
- Рекрутинг
- Diabetes and Endocrine Centre
-
Главный следователь:
- Duncan Browne
-
Контакт:
- Diabetes and Renal Research Team (Truro)
- Номер телефона: +44 1872254655
- Электронная почта: rcht.diabetesresearch@nhs.net
-
-
Devon
-
Exeter, Devon, Соединенное Королевство, EX2 5DW
- Рекрутинг
- NIHR Exeter Clinical Research Facility
-
Контакт:
- BRIGHT Study Research Team
- Номер телефона: +44 1392408181
- Электронная почта: rduh.brightstudy@nhs.net
-
Главный следователь:
- Angus Jones
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Метод выборки
Исследуемая популяция
ARM 1: Participants who have previously taken part in the StartRight study (NCT03737799) with consent to re-contact for future research (from sites across the United Kingdom (UK)).
ARM 2: Participants who have previously taken part in the StartRight study or other diabetes research cohorts, as well as patients referred by their clinician or self-referred (across the UK).
Описание
ARM 1
Inclusion Criteria:
- Previously recruited to the StartRight study (NCT03737799) with consent to be contacted for further research
- Clinical diagnosis of diabetes & Insulin treated
- Able and willing to provide informed consent/assent.
- Aged 18 years or older.
ARM 2
Inclusion Criteria:
- Clinical diagnosis of Type 1 diabetes
- Known C-peptide, measured as part of previous research or as part of diabetes clinical care OR Where C-peptide is not measured, participant must be within 7 years of diagnosis and have at least 1 positive islet antibody, measured at any time since diabetes diagnosis.
- Where measured C-peptide is >600pmol/L, previous positive islet autoantibodies.
- Able and willing to provide informed consent
- Aged 18 years or older
Exclusion Criteria:
- Renal failure defined by eGFR <30mL/min/1.73 m²
Учебный план
Как устроено исследование?
Детали дизайна
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Arm 1
Adults (aged >= 18 years) diagnosed with diabetes for >3 years, treatment with insulin, and previously taken part in the StartRight study with consent to re-contact.
|
Наблюдательный
|
|
Arm 2
Adults (aged >= 18 years) diagnosed with type 1 diabetes.
Known level of insulin secretion, measured using a C-peptide test after diabetes diagnosis.
Participants will have had C-peptide measured as part of a previous research study or as part of their diabetes clinical care.
Where C-peptide is not measured, participant must be within 7 years of diagnosis and have at least 1 positive islet antibody, measured at any time since diabetes diagnosis.
|
Наблюдательный
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Capillary C-peptide measured 1-5 hours after a meal containing carbohydrates (Arm 1)
Временное ограничение: 1 day during study participation
|
Analysis of Arm 1 will assess the relationship between home post-meal C-peptide (measured serially from within 12 months of diagnosis up to 10 years post-diagnosis, through extension of an existing study), and the secondary outcomes listed below.
This will be assessed as longitudinal change over time (Arm 1 cohort) and cross-sectionally using the most recent visit data from the combined Arm 1 and Arm 2 cohorts.
|
1 day during study participation
|
|
Plasma and capillary C-peptide (Arm 2)
Временное ограничение: 90-minutes post baseline
|
Primary analysis for Arm 2 will assess the relationship between home capillary C-peptide measurements (post-meal, assessed individually & as the average of up to three measurements, and 90-minute post-mixed meal tolerance test) and 90-minute plasma C-peptide measured during a mixed meal tolerance test conducted at a research centre.
Secondary analysis will compare the relationship between C-peptide measures and the continuous glucose monitoring secondary outcome listed below.
|
90-minutes post baseline
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Questionnaire assessed hypoglycaemia and hypoglycaemia unawareness (Arm 1 & Arm 2)
Временное ограничение: Symptoms experienced during 4 weeks prior to study enrolment
|
Results from analysis of data from Modified Clarke/Edinburgh Hypoglycaemia History questionnaire
|
Symptoms experienced during 4 weeks prior to study enrolment
|
|
Questionnaire assessed emotional burden (Arm 1 & Arm 2)
Временное ограничение: Symptoms experienced during 4 weeks prior to study enrolment
|
Results from analysis of data from Diabetes Distress Scale questionnaire
|
Symptoms experienced during 4 weeks prior to study enrolment
|
|
Questionnaire assessed quality of life/wellbeing (Arm 1 & Arm 2)
Временное ограничение: Symptoms experienced during 4 weeks prior to study enrolment
|
Results from analysis of data from Veterans RAND 12-Item Health Survey (VR-12) questionnaire
|
Symptoms experienced during 4 weeks prior to study enrolment
|
|
Changes/updates to diabetes treatment, complications and healthcare utilisation for relevant medical conditions since previous study visit (Arm 1)
Временное ограничение: Up to 3 years prior to study enrolment
|
Data collected during current study visit combined with data from previous study visit.
|
Up to 3 years prior to study enrolment
|
|
Continuous glucose monitor measured glucose variability and hypoglycaemia (Arm 2)
Временное ограничение: 14 days during study participation
|
Analysis for Arm 2 will compare the relationship of different C-peptide measures to glucose variability (assessed as Standard Deviation glucose) and hypoglycaemia (assessed as % time glucose below 3mmol/L), derived from 14 days of continuous interstitial glucose monitoring
|
14 days during study participation
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания эндокринной системы
- Метаболические заболевания
- Аутоиммунные заболевания
- Заболевания иммунной системы
- Нарушения метаболизма глюкозы
- Пищевые и метаболические заболевания
- Сахарный диабет
- Сахарный диабет, тип 1
- Администрация медицинских услуг
- Качество здравоохранения
- Оценка результатов, здравоохранение
- Оценка результатов и процессов, здравоохранение
- Бдительный ожидание
Другие идентификационные номера исследования
- 2507771
- 2-SRA-2025-1637-S-B (Другой номер гранта/финансирования: Breakthrough T1D (formerly Juvenile Diabetes Research Foundation (JDRF)))
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .